Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 255-268

  Karageorgopoulos, Drosos E ^a   Wang, Rui ^b   Yu, Xu hong ^c   Falagas, Matthew E ^a,d,e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c The 305 Hospital of Chinese PLA   (China)

^d HENRY DUNANT HOSPITAL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biological transport; Cell wall; Enterobacteriaceae; Microbial drug resistance; Mutation; Urinary tract infections; Virulence

Indexed keywords

CIPROFLOXACIN; FOSFOMYCIN; FOSFOMYCIN CALCIUM; FOSFOMYCIN TROMETAMOL; NITROFURANTOIN; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; BRONCHOPNEUMONIA; CHRONIC BRONCHITIS; CHRONIC OSTEOMYELITIS; CYSTITIS; DRUG COST; DRUG EFFICACY; EMPHYSEMA; EMPYEMA; ENDOMETRIOSIS; ENDOMETRITIS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FECES MICROFLORA; GRAM NEGATIVE BACTERIUM; GROWTH RATE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; LUNG ABSCESS; MORGANELLA MORGANII; NONHUMAN; PERTUSSIS; PNEUMONIA; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SEPTICEMIA; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; SUPPURATIVE OTITIS MEDIA; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; FOSFOMYCIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MUTATION; PSEUDOMONAS AERUGINOSA;

EID: 84862936625     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr466     Document Type: Article

References (92)

1. Hendlin D, Stapley EO, Jackson M et al. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science (New York, NY) 1969; 166: 122-3.
2. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008; 27: 439-43.
3. Falagas ME, Maraki S, Karageorgopoulos DE et al. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin. Int J Antimicrob Agents 2010; 35: 497-9.
4. Falagas ME, Kastoris AC, Kapaskelis AM et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50.
5. Skarzynski T, Mistry A, Wonacott A et al. Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin. Structure 1996; 4: 1465-74.
6. Tsuruoka T, Miyata A, Yamada Y. Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K-12. J Antibiot (Tokyo) 1978; 31: 192-201.
7. Kadner RJ, Winkler HH. Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli. J Bacteriol 1973; 113: 895-900.
8. Cordaro JC, Melton T, Stratis JP et al. Fosfomycin resistance: selection method for internal and extended deletions of the phosphoenolpyruvate:sugar phosphotransferase genes of Salmonella typhimurium. J Bacteriol 1976; 128: 785-93.
9. Huang Y, Lemieux MJ, Song J et al. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 2003; 301: 616-20.
10. Levy S, Zeng GQ, Danchin A. Cyclic AMP synthesis in Escherichia coli strains bearing known deletions in the pts phosphotransferase operon. Gene 1990; 86: 27-33.
11. Sakamoto Y, Furukawa S, Ogihara H et al. Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli. Biosci Biotechnol Biochem 2003; 67: 2030-3.
12. Nilsson AI, Berg OG, Aspevall O et al. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 2850-8.
13. Takahata S, Ida T, Hiraishi T et al. Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents 2010; 35: 333-7.
14. Kim DH, Lees WJ, Kempsell KE et al. Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry 1996; 35: 4923-8.
15. Venkateswaran PS, Wu HC. Isolation and characterization of a phosphonomycin-resistant mutant of Escherichia coli K-12. J Bacteriol 1972; 110: 935-44.
16. Kumar S, Parvathi A, Hernandez RL et al. Identification of a novel UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) from Vibrio fischeri that confers high fosfomycin resistance in Escherichia coli. Arch Microbiol 2009; 191: 425-9.
17. Horii T, Kimura T, Sato K et al. Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother 1999; 43: 789-93.
18. Arca P, Rico M, Brana AF et al. Formation of an adduct between fosfomycin and glutathione: a new mechanism of antibiotic resistance in bacteria. Antimicrob Agents Chemother 1988; 32: 1552-6.
19. Leon J, Garcia-Lobo JM, Navas J et al. Fosfomycin-resistance plasmids determine an intracellular modification of fosfomycin. J Gen Microbiol 1985; 131: 1649-55.
20. Rigsby RE, Fillgrove KL, Beihoffer LA et al. Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily. Methods Enzymol 2005; 401: 367-79.
21. Wachino J, Yamane K, Suzuki S et al. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediatedfosfomycin-modifying enzymes. Antimicrob Agents Chemother 2010; 54: 3061-4.
22. Garcia P, Arca P, Evaristo Suarez J. Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate. Antimicrob Agents Chemother 1995; 39: 1569-73.
23. Kobayashi S, Kuzuyama T, Seto H. Characterization of the fomA and fomB gene products from Streptomyces wedmorensis, which confer fosfomycin resistance on Escherichia coli. Antimicrob Agents Chemother 2000; 44: 647-50.
24. Shimizu M, Shigeobu F, Miyakozawa I et al. Novel fosfomycin resistance of Pseudomonas aeruginosa clinical isolates recovered in Japan in 1996. Antimicrob Agents Chemother 2000; 44: 2007-8.
25. Tsuruoka T, Yamada Y. Characterization of spontaneous fosfomycin (phosphonomycin)-resistant cells of Escherichia coli B in vitro. J Antibiot (Tokyo) 1975; 28: 906-11.
26. Rodri{dotless}́guez-Rojas A, Macia MD, Couce A et al. Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections. PLoS One 2010; 5: e10193.
27. MacLeod DL, Barker LM, Sutherland JL et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 2009; 64: 829-36.
28. Ellington MJ, Livermore DM, Pitt TL et al. Mutators among CTX-M b-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother 2006; 58: 848-52.
29. Denamur E, Bonacorsi S, Giraud A et al. High frequency of mutator strains among human uropathogenic Escherichia coli isolates. J Bacteriol 2002; 184: 605-9.
30. Talarmin A, Dubrous P, Gerome P et al. Study of Pseudomonas aeruginosa serotype O12 isolates with a common antibiotic susceptibility pattern. Eur J Clin Microbiol Infect Dis 1996; 15: 459-64.
31. Ferrara A, Migliori GB, Piccioni PD et al. Influence of experimental conditions on in vitro activity of fosfomycin trometamol and emergence of resistant variants. In: Neu HC, Williams JD, eds. New Trends in Urinary Tract Infections: The Single-Dose Therapy. Basel: S Karger, 1988; 269-83.
32. Lerner SA, Price S, Kulkarni S. Microbiological studies of fosfomycin trometamol against urinary isolates in vitro. In: Neu HC, Williams JD, eds. New Trends in Urinary Tract Infections: The Single-Dose Therapy. Basel: S Karger, 1988; 121-9.
33. Courtieu AL, Drugeon H, Billaudel S. Susceptibility to fosfomycin of hospital strains isolated in Nantes (France). Frequency of mutation to resistance. Chemotherapy 1977; 23 Suppl 1: 25-36.
34. Galan JC, Tato M, Baquero MR et al. Fosfomycin and rifampin disk diffusion tests for detection of Escherichia coli mutator strains. J Clin Microbiol 2004; 42: 4310-2.
35. Carmen Conejo M, Amblar G, Pascual A et al. Detection of hypermutable Escherichia coli strains in a collection of clinical isolates by the fosfomycin-rifampin disk method. J Clin Microbiol 2006; 44: 2672.
36. Greenwood D. Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis. Infection 1986; 14: 186-9.
37. Falagas ME, Vouloumanou EK, Togias AG et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1862-77.
38. Naber KG, Thyroff-Friesinger U. Spectrum and susceptibility of pathogens causing acute uncomplicated lower UTI in females and its correlation to bacteriologic outcome after single dose therapy with fosfomycin trometamol versus ofloxacin/co-trimoxazole. Infection 1992; 20 Suppl 4: S296-301.
39. Meissner A, Haag R, Rahmanzadeh R. Adjuvant fosfomycin medication in chronic osteomyelitis. Infection 1989; 17: 146-51.
40. Nissen LR, Jacobsen J, Ravn TJ et al. Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically ill patients with pneumonia. Infection 1986; 14: 246-9.
41. Bacardi{dotless}́ R, Tornos J, Moga I et al. Treatment of respiratory infections with fosfomycin. Chemotherapy 1977; 23 Suppl 1: 343-7.
42. Bonora V, Lozano C, Santos M et al. Fosfomycin in treatment of respiratory bacterial infections. Chemotherapy 1977; 23 Suppl 1: 337-41.
43. Gobernado M, Perez de Leon A, Santos M et al. Fosfomycin in the treatment of gynecological infections. Chemotherapy 1977; 23 Suppl 1: 287-92.
44. Honorato J, Perez Ortola R, Masso R et al. Fosfomycin in acute bronchopneumopathies. Chemotherapy 1977; 23 Suppl 1: 331-6.
45. Rodri{dotless}́guez A, Gallego A, Olay T et al. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy 1977; 23 Suppl 1: 247-58.
46. Sole Puyo JM, Poch Vin{ogonek} als R. Treatment of chronic suppurated otitis with fosfomycin. Chemotherapy 1977; 23 Suppl 1: 379-91.
47. Fernandez-Valencia JE, Saban T, Canedo T et al. Fosfomycin in osteomyelitis. Chemotherapy 1976; 22: 121-34.
48. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother 2005; 56: 243-6.
49. Hendlin D, Celozzi E, Weissberger B et al. Effect of fosfomycin on the fecal microflora of man. Chemotherapy 1977; 23 Suppl 1: 117-26.
50. Reeves DS, Holt HA, Bywater MJ et al. Effect of fosfomycin trometamol on the faecal flora of eight healthy volunteers. In: Neu HC, Williams JD, eds. New Trends in Urinary Tract Infections: The Single-Dose Therapy. Basel: S Karger, 1988; 292-8.
51. Hara T, Araake M, Watabe H. Antibacterial activities of fosfomycin against several fresh clinical isolates-comparison of the test methods for antibacterial activity. Jpn J Antibiot 2002; 55: 844-54.
52. Oteo J, Orden B, Bautista V et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009; 64: 712-7.
53. Andreu A, Planells I. Etiologi{dotless}́a de la infección urinaria baja adquirida en la comunidad y resistencia de Escherichia coli a los antimicrobianos de primera li{dotless}́nea. Estudio nacional multicéntrico. Medicina Cli{dotless}́nica 2008; 130: 481-6.
54. Gamero Delgado MC, Garcia-Mayorgas AD, Rodriguez F et al. Susceptibility and resistance of Pseudomonas aeruginosa to antimicrobial agents. Rev Esp Quimioter 2007; 20: 230-3.
55. Honderlick P, Cahen P, Gravisse J et al. Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006? Pathol Biol (Paris) 2006; 54: 462-6.
56. Junquera S, Loza E, Baquero F. Evolución del patrón de sensibilidad de aislados de Escherichia coli en urocultivos procedentes del medio hospitalario y extrahospitalario. Enferm Infecc Microbiol Cli{dotless}́n 2005; 23: 197-201.
57. Lorente Gari{dotless}́n JA, Placer Santos J, Salvado Costa M et al. Antibiotic resistance transformation in community-acquired urinary infections. Rev Clin Esp 2005; 205: 259-64.
58. Rodri{dotless}́guez Lopez FC, Franco-Alvarez de Luna F, Gordillo Urbano RM et al. Microorganisms isolated from outpatient urine samples and antimicrobial susceptibility over a 12-year period. Rev Esp Quimioter 2005; 18: 159-67.
59. Gobernado M. Fosfomycin. Rev Esp Quimioter 2003; 16: 15-40.
60. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 2003; 22 Suppl 2: 79-83
61. Bert F, Lambert-Zechovsky N. Antibiotic resistance patterns in Pseudomonas aeruginosa: an 8-year surveillance study in a French hospital. Int J Antimicrob Agents 1997; 9: 107-12.
62. Philippon A, Arlet G, Lagrange P. Escherichia coli: fréquence de résistance et évolution à divers antibiotiques urinaires dont la fosfomycine en milieu hospitalier (11816 souches, 1991-1995). Méd Malad Infect 1996; 26: 539-41.
63. Dámaso D, Moreno-Lopez M, Martinez-Beltran J. Evolution of sensitivity to fosfomycin in bacteria isolated in 1973, 1974 and 1975 in the Servicio de Microbiologia y Epidemiologia of the 'Clinica Puerta de Hierro', Madrid. Chemotherapy 1977; Suppl 1: 104-11.
64. Li Pira G, Pruzzo C, Schito GC. Monuril and modification of pathogenicity traits in resistant microorganisms. Eur Urol 1987; 13 Suppl 1: 92-7.
65. Marchese A, Gualco L, Debbia EA et al. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 2003; 22 Suppl 2: 53-9.
66. Gordon DM, Riley MA. A theoretical and experimental analysis of bacterial growth in the bladder. Mol Microbiol 1992; 6: 555-62.
67. Castaneda-Garcia A, Rodriguez-Rojas A, Guelfo JR et al. The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa. J Bacteriol 2009; 191: 6968-74.
68. De Groote VN, Fauvart M, Kint CI et al. Pseudomonas aeruginosa fosfomycin resistance mechanisms affect non-inherited fluoroquinolone tolerance. J Med Microbiol 2011; 60: 329-36.
69. Fauvart M, De Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol 2011; 60: 699-709.
70. Olsson-Liljequist B, Burman LG. Introducing fosfomycin for surgical prophylaxis-emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures. Scand J Infect Dis 1993; 25: 725-33.
71. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-71.
72. Kasai T, Tsuruoka T. Pathogenicity of fosfomycin-resistant strains isolated from Escherichia coli. Jpn J Antibiot 1999; 52: 34-40.
73. Lemieux MJ, Huang Y, Wang DN. Glycerol-3-phosphate transporter of Escherichia coli: structure, function and regulation. Res Microbiol 2004; 155: 623-9.
74. Kok M, Bron G, Erni B et al. Effect of enzyme I of the bacterial phosphoenolpyruvate:sugar phosphotransferase system (PTS) on virulence in a murine model. Microbiology 2003; 149: 2645-52.
75. Brown ED, Vivas EI, Walsh CT et al. MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli. J Bacteriol 1995; 177: 4194-7.
76. Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997; 53: 637-56.
77. Schito GC, Chezzi C, Nicoletti G et al. Susceptibility of frequent urinary pathogens to fosfomycin trometamol and eight other antibiotics: results of an Italian multicenter survey. Infection 1992;Suppl 4: S291-5.
78. Roussos N, Karageorgopoulos DE, Samonis G et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009; 34: 506-15.
79. Matzi V, Lindenmann J, Porubsky C et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother 2010; 65: 995-8.
80. Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000; 44: 1771-7.
81. Thi TD, Lopez E, Rodriguez-Rojas A et al. Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. J Antimicrob Chemother 2011; 66: 531-8.
82. Denamur E, Tenaillon O, Deschamps C et al. Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli. Genetics 2005; 171: 825-7.
83. Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos Trans R Soc Lond B Biol Sci 1999; 354: 721-38.
84. Bjorkman J, Nagaev I, Berg OG et al. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000; 287: 1479-82.
85. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenemhydrolyzing enzymes. Future Microbiol 2011; 6: 653-66.
86. Samonis G, Maraki S, Karageorgopoulos DE et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2011 [Epub ahead of print].
87. Cai Y, Fan Y, Wang R et al. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J Antimicrob Chemother 2009; 64: 563-6.
88. Souli M, Galani I, Boukovalas S et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011; 55: 2395-7.
89. Rodriguez-Rojas A, Couce A, Blazquez J. Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54: 4948-9.
90. Giraud A, Matic I, Radman M et al. Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob Agents Chemother 2002; 46: 863-5.
91. Martinez JL, Baquero F, Andersson DI. Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics. Curr Opin Pharmacol 2011; 11: 439-45.
92. Levin BR. Minimizing potential resistance: a population dynamics view. Clin Infect Dis 2001; 33 Suppl 3: S161-9.